Delving into the Latest Updates on The Institute For Neurosciences of Montpellier with Synapse

Overview

Tags

Nervous System Diseases

Nanobody

Bispecific antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1

Top 5 Drug Type	Count

Nanobody	1
Bispecific antibody	1

Top 5 Target	Count

mGluR2(Metabotropic glutamate receptor 2)	1

Objectives The transparent surface of the eye, called the cornea, plays a crucial role in transmitting light to the retina and in protecting the eye. On its external surface, the cornea is composed of a constantly renewing multistratified epithelium. This mechanism is fueled by stem cells located in the limbus (the transition zone between the cornea and the sclera). Limbal Stem Cell Deficiency (LSCD) is characterized by a decrease or cessation of epithelial renewal and neovascularization of the cornea. Consequently, the cornea loses its integrity and transparency. This visually impairing condition is currently in a therapeutic impasse as only autologous limbal or allogeneic corneal grafts are viable options, but they pose significant risks to patients.
Studies have shown that the oral cavity contains stem cells that can be isolated, cultured, and transdifferentiated into limbal stem cells (LSCs). However, to date, these studies are limited, and no protocol has been validated. In this study, the advantage of the accessibility of the oral cavity is used to develop a protocol for differentiating cells from the oral mucosa into limbal stem cells (LSCs) for use in a future clinical trial with patients.
Methodology This prospective monocentric study will be conducted on patients from the ophthalmology department of the Montpellier University Hospital who have an indication for conjunctival reconstruction. After obtaining consent from the patients, cells from the oral wall will be sent to the tissue bank of the Montpellier University Hospital, where they will be cultured. Finally, the transdifferentiation steps will be analyzed by the "Eye" research team at the Institute of Neuroscience in Montpellier, which is collaborating on the project. The investigators have established objective factors to assess the success of the developed protocol based on the literature : (i) > 3% of stem cells in primary cultures, (ii) <10% aborted colonies, (iii) Expression of LSC markers (Pax6, Krt14, p63).

Start Date19 Jun 2024

Sponsor / Collaborator

University Hospital of Montpellier

[+1]

100 Clinical Results associated with The Institute For Neurosciences of Montpellier

Login to view more data

0 Patents (Medical) associated with The Institute For Neurosciences of Montpellier

Login to view more data

154

Literatures (Medical) associated with The Institute For Neurosciences of Montpellier

01 Nov 2025·JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

SCORE2 ‐Older Persons ( SCORE2 ‐ OP ): Validation and Added Value of Excessive Daytime Sleepiness in a French Cohort

Article

Author: Empana, Jean‐Philippe ; Helmer, Catherine ; Cavaillès, Clémence ; Dauvilliers, Yves ; Jaussent, Isabelle ; Mura, Thibault ; Andriambelosoa, Tahiana

ABSTRACT:

Background:

Cardiovascular diseases are the leading cause of death worldwide, particularly in older adults. While the Systematic Coronary Risk Evaluation 2‐Older Persons (SCORE2‐OP) model estimates 10‐year cardiovascular risk in this population, its validation in general European cohorts remains limited. Given growing relationships between sleep disturbances and cardiovascular risk, we aimed to validate SCORE2‐OP in a French cohort and assess the incremental value of excessive daytime sleepiness (EDS).

Methods:

We included 4626 participants aged 70+ from the Three‐City cohort, without cardiovascular disease and dementia at baseline. The SCORE2‐OP model calibrated for low‐cardiovascular risk regions was used to estimate 10‐year cardiovascular risk. Calibration was assessed using observed‐to‐expected cumulative incidence ratios and calibration curves; discrimination using the area under the curve (AUC). Cox proportional hazards models examined associations between sleep symptoms (poor sleep quality, EDS, insomnia symptoms, sleep apnea [proxy]) and cardiovascular events. Incremental predictive value of significant symptoms was quantified by ΔAUC and net reclassification improvement (NRI).

Results:

Over 10 years, the observed cumulative incidence of fatal and non‐fatal coronary heart disease or stroke was 10.55%; 95% confidence intervals (CI) = (9.62; 11.48), while the SCORE2‐OP predicted risk was 14.04%; 95% CI = (13.85; 14.24), yielding an observed‐to‐expected ratio of 0.75; 95% CI = (0.69; 0.80). Discrimination was moderate (AUC = 61.71%, 95% CI = [58.64; 64.78]). EDS was the only sleep symptom independently associated with cardiovascular events (adjusted hazard‐ratio = 1.32, 95% CI = [1.05; 1.65]). Adding EDS to SCORE2‐OP did not improve overall discrimination (ΔAUC = +0.72%, 95% CI = [−0.05; 1.50]) or reclassification (NRI = +1.33%, 95% CI = [−3.27; 5.93]). Sex‐stratified analyses showed significant improvement in discrimination in men (ΔAUC = +2.27%, 95% CI = [0.54; 4.00]), but not in women. Moreover, EDS improved reclassification in low (< 7.5%) and intermediate (7.5%–15%) cardiovascular risk groups (NRI = +12%, 95% CI = [3.56; 20.43] and NRI = +12.44%, 95% CI = [7.23; 17.65], respectively).

Conclusions:

In this French cohort, SCORE2‐OP overestimated cardiovascular risk and showed moderate discrimination. EDS improved SCORE2‐OP performance in intermediate cardiovascular risk groups where treatments are uncertain, highlighting its clinical relevance; although implications for prevention strategies require further study.

01 Sep 2025·SLEEP MEDICINE

Letter to the editor: “Towards a consistent assessment of sex hormones and thermic curve in reproduction life related Kleine-Levin syndrome patients and controls”

Letter

Author: Jaussent, Isabelle ; Billiard, Michel

01 Aug 2025·SLEEP MEDICINE REVIEWS

Shedding light on microsleep episodes for comprehensive sleepiness assessment: a narrative review

Review

Author: Barateau, Lucie ; Dauvilliers, Yves ; Baillieul, Sébastien ; Pépin, Jean-Louis ; Tamisier, Renaud ; Peter-Derex, Laure ; Davin, Aurélie

Excessive daytime sleepiness is a consistent and common symptom in sleep medicine. It represents a major public health problem due to its association with significant impairments in quality of life, work productivity, and driving ability. Objective clinical tests for assessing excessive daytime sleepiness follow the universal American academy of sleep medicine scoring classification, which overlooks short intrusions of sleep during wake states, known as microsleep episodes. This narrative review provides a comprehensive summary of the existing literature concerning microsleep episodes, highlighting their significance and potential additional value in the context of sleepiness assessment. Moreover, due to the related attention lapses they cause, microsleep episodes may have significant implications for cognitive performance and road traffic accidents. These are discussed along with potential effective countermeasures. This review concludes by proposing an innovative framework for enriching excessive daytime sleepiness evaluation by integrating the assessment of microsleep episodes into routine clinical tests. Such an approach promises to provide valuable insights into the dynamics of sleepiness and could significantly enhance excessive daytime sleepiness assessment and management through personalized medicine.

100 Deals associated with The Institute For Neurosciences of Montpellier

Login to view more data

100 Translational Medicine associated with The Institute For Neurosciences of Montpellier

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 11 Mar 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

1

Login to view more data